An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
Daniel Morgensztern(Barnes-Jewish Hospital), Pilar Garrido(Hospital Universitario Ramón y Cajal), Olga Burdaeva(Universitair Ziekenhuis Leuven), Ionel Mitrica(GlaxoSmithKline (United States)), С. В. Орлов(St Petersburg University), Ignacio Delgado(Universitat Autònoma de Barcelona), Nina Karaseva, М. В. Шомова, José Trigo(Heidelberg University), Katherine L. Baker-Neblett(GlaxoSmithKline (United States)), Primo N. Lara(UC Davis Comprehensive Cancer Center), M. Phillip DeYoung(Johnson & Johnson (United States)), Ulrik Lassen(Rigshospitalet), Manuel Dómine(Chinese Academy of Medical Sciences & Peking Union Medical College), Enriqueta Felip(Institut Català d'Ornitologia), Xiaowei Wang(The Eighth Hospital of Xi'an), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Yan Li(The University of Texas Southwestern Medical Center), James Vasquez(GlaxoSmithKline (United States))
Cited by 24
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k